Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Collaborative work behind the scenes makes cancer breakthroughs possible

When we talk about breakthroughs in cancer research, most focus on the moment of discovery: a new therapy, a promising trial result, or a headline-grabbing study.

May 08, 2026

Vol.52 No.18

By Annaliese Daniels

Drugs & Targets

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA has accepted a New Drug Application for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab. The Prescription Drug User Fee Act target action date is Feb. 27, 2027.

May 01, 2026

Vol.52 No.17

Drugs & Targets

Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

Nuvalent announced the submission of a New Drug Application to FDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive non-small cell lung cancer.

April 10, 2026

Vol.52 No.14

In Brief

Neal Meropol named PI of ASCO’s TAPUR study

Neal J. Meropol was named principal investigator of the American Society of Clinical Oncology’s Targeted Agent and Profiling Utilization Registry study.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, according to a study led by NYU Langone Health, its Perlmutter Cancer Center, and its Center for the Investigation of Environmental Hazards.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

FDA approved Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

February 27, 2026

Vol.52 No.08

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

YOU MAY BE INTERESTED IN

Collaborative work behind the scenes makes cancer breakthroughs possible

FDA accepts NDA for zipalertinib for NSCLC with mutations

Nuvalent submits NDA to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

Neal Meropol named PI of ASCO’s TAPUR study

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login